Latest news and press releases about Lucid Diagnostics Inc. (LUCD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma.
Price
| Price | $0.78 |
| Market Cap | $149M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 13.87 |
| EV / EBITDA | -3.32 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -404.34% |
| Return on Invested Capital | -141.44% |
| Return on Assets | -134.18% |
| Gross Margin | -25.79% |
| Operating Margin | -930.85% |
| Net Margin | -959.76% |
Related companies: APYX · AVR · IRD · IXHL · OWLT · RCEL · RPID
Explore sector: Healthcare · Medical - Devices
More sections of LUCD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks